Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 2/2011

01-04-2011 | Original Article

Expression of thrombospondin-1 and Ski are prognostic factors in advanced gastric cancer

Authors: Toshihiro Nakao, Nobuhiro Kurita, Masato Komatsu, Kozo Yoshikawa, Takashi Iwata, Toru Utsunomiya, Mitsuo Shimada

Published in: International Journal of Clinical Oncology | Issue 2/2011

Login to get access

Abstract

Background

It has been suggested that thrombospondin-1 (TSP-1) plays a role in angiogenesis in many cancers. In addition, TSP-1 has been shown to suppress tumor growth by activating transforming growth factor-β (TGF-β). Recent studies have shown that Ski protein suppresses TGF-β signaling. The aim of this study was to investigate the role of TSP-1 and Ski expression in advanced gastric cancer.

Methods

Sixty-five recurrent patients who underwent resection of advanced gastric cancer (n = 62) or who had unresectable tumors (n = 3) between March 2003 and October 2007 participated in this study. All patients were treated with chemotherapy after collection of the tumor tissue. Twenty-three of them were also treated with chemotherapy before collection of the tumor specimen. The TSP-1, Ski, vascular endothelial growth factor (VEGF) and TGF-β protein expression were examined by immunohistochemical staining, and microvessels in the tumor were counted.

Results

There were 17 (26.2%) gastric cancers with positive staining for TSP-1. There was no relationship between TSP-1 expression and clinicopathological factors.

TSP-1 expression had positive association with VEGF expression, microvessel density (MVD) and TGF-β expression. However, there was no relationship between TSP-1 and Ski expression. TSP-1 correlated with good survival in advanced gastric cancer, and Ski correlated with poor survival in the patients with TGF-β-positive advanced gastric cancer.

Conclusions

This study shows that TSP-1 enhances angiogenesis due to its positive correlation with VEGF and MVD, and is a good prognostic factor for survival in advanced gastric cancer. This study also shows that Ski inhibits the prolonged effects of TGF-β for survival in advanced gastric cancer.

Literature
  1. World Health Organization. http://​www.​who.​int/​mediacentre/​factsheets/​fs297/​en/​
  2. Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74–108PubMedView Article
  3. Ganguly P (1971) Isolation and properties of a thrombin-sensitive protein from human blood platelets. J Biol Chem 246(13):4286–4290PubMed
  4. Maeda K, Nishiguchi Y, Kang SM et al (2001) Expression of thrombospondin-1 inversely correlated with tumor vascularity and hematogenous metastasis in colon cancer. Oncol Rep 8(4):763–766PubMed
  5. Yamaguchi M, Sugio K, Ondo K et al (2002) Reduced expression of thrombospondin-1 correlates with a poor prognosis in patients with non-small cell lung cancer. Lung Cancer 36(2):143–150PubMedView Article
  6. Grossfeld GD, Ginsberg DA, Stein JP et al (1997) Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. J Natl Cancer Inst 89(3):219–227PubMedView Article
  7. Morelli D, Lazzerini D, Cazzaniga S et al (1998) Evaluation of the balance between angiogenic and antiangiogenic circulating factors in patients with breast and gastrointestinal cancers. Clin Cancer Res 4(5):1221–1225PubMed
  8. Kasper HU, Ebert M, Malfertheiner P et al (2001) Expression of thrombospondin-1 in pancreatic carcinoma: correlation with microvessel density. Virchows Arch 438:116–120PubMedView Article
  9. Yamashita Y, Kurohiji T, Tuszynski GP et al (1998) Plasma thrombospondin levels in patients with colorectal carcinoma. Cancer 82:632–638PubMedView Article
  10. Heldin CH, Miyazono K, ten Dijke P (1997) TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 390:465–471PubMedView Article
  11. Maeda K, Nishiguchi Y, Yashiro M et al (2000) Expression of vascular endothelial growth factor and thrombospondin-1 in colorectal carcinoma. Int J Mol Med 5:373–378PubMed
  12. Poon RT, Chung KK, Cheung ST et al (2004) Clinical significance of thrombospondin 1 expression in hepatocellular carcinoma. Clin Cancer Res 10:4150–4157PubMedView Article
  13. Pratt DA, Miller WR, Dawes J (1989) Thrombospondin in malignant and non-malignant breast tissue. Eur J Cancer Clin Oncol 25:343–350PubMedView Article
  14. Luo Ski K, Sno N (2004) Negative regulators of TGF-beta signaling. Curr Opin Genet Dev 14:65–70View Article
  15. Zhang J, Ito R, Oue N et al (2003) Expression of thrombospondin-1 is correlated with microvessel density in gastric carcinoma. Virchows Arch 442:563–568PubMed
  16. Takahata M, Inoue Y, Tsuda H et al (2009) SKI and MEL1 cooperate to inhibit transforming growth factor-beta signal in gastric cancer cells. J Biol Chem 284:3334–3344PubMedView Article
  17. Saito H, Tsujitani S, Ikeguchi M et al (1998) Relationship between the expression of vascular endothelial growth factor and the density of dendritic cells in gastric adenocarcinoma tissue. Br J Cancer 78:1573–1577PubMedView Article
  18. Saito H, Tsujitani S, Oka S et al (1999) The expression of transforming growth factor-beta1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma. Cancer 86:1455–1462PubMedView Article
  19. Vermeulen PB, Gasparini G, Fox SB et al (1996) Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 32A:2474–2484PubMedView Article
  20. Fondevila C, Metges JP, Fuster J et al (2004) p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. Br J Cancer 90:206–215PubMedView Article
  21. Greenaway J, Lawler J, Moorehead R et al (2007) Thrombospondin-1 inhibits VEGF levels in the ovary directly by binding and internalization via the low density lipoprotein receptor-related protein-1 (LRP-1). J Cell Physiol 210:807–818PubMedView Article
  22. Poon RT, Chung KK, Cheung ST et al (2004) Clinical significance of thrombospondin 1 expression in hepatocellular carcinoma. Clin Cancer Res 10:4150–4157PubMedView Article
  23. Hironaka S, Hasebe T, Kamijo T et al (2002) Biopsy specimen microvessel density is a useful prognostic marker in patients with T(2–4)M(0) esophageal cancer treated with chemoradiotherapy. Clin Cancer Res 8:124–130PubMed
  24. Kiyono K, Suzuki HI, Morishita Y et al (2009) c-Ski overexpression promotes tumor growth and angiogenesis through inhibition of transforming growth factor-beta signaling in diffuse-type gastric carcinoma. Cancer Sci 100:1809–1816PubMedView Article
Metadata
Title
Expression of thrombospondin-1 and Ski are prognostic factors in advanced gastric cancer
Authors
Toshihiro Nakao
Nobuhiro Kurita
Masato Komatsu
Kozo Yoshikawa
Takashi Iwata
Toru Utsunomiya
Mitsuo Shimada
Publication date
01-04-2011
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 2/2011
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-010-0147-5

Other articles of this Issue 2/2011

International Journal of Clinical Oncology 2/2011 Go to the issue

Case Report

Metastatic collecting duct carcinoma of the kidney responded to sunitinib

Original Article

Usage of granulocyte colony-stimulating factor every 2 days is clinically useful and cost-effective for febrile neutropenia during early courses of chemotherapy

Original Article

Hepatic resection with or without adjuvant iodine-131-lipiodol for hepatocellular carcinoma: a comparative analysis

Review Article

Proteomic analysis of soft tissue sarcoma

Review Article

Cryoimmunology for malignant bone and soft-tissue tumors

Case Report

Full-thickness chest-wall resection followed by thorax reconstruction for recurrent malignant phyllodes tumor
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits